Diagnosis of the disease requires the combination of clinical performance, imaging, laboratory testing, and pathological activation. A platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment. Individualised development of treatments for treatment and management of fetal lung cancer, usually including drug therapy, rehabilitation intervention, and regular follow-up to multiple-dimensional management, is required.
In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment requires close monitoring of efficacy and adverse reactions and timely adjustment according to changes in the disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of embryonic lung cancer.
The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, to provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.